Kodiak Sciences Shares Hit 52-Week High After Positive Phase 3 Trial

By Chris WackKodiak Sciences shares more than doubled Monday after the company said its Phase 3 study for Zenkuda and tabirafusp-ted met the primary endpoints for both drugs in patients with wet age-related macular degeneration.The stock was 156% higher, at $82.80, in morning trade, its 52-week hig…